Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have earned a consensus rating of “Hold” from the four ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $16.67.

Several research analysts have weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Canaccord Genuity Group increased their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price target for the stock from $25.00 to $18.00 in a research note on Friday, August 16th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in Atara Biotherapeutics by 8,916.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after purchasing an additional 4,903,159 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Atara Biotherapeutics by 49.5% during the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after buying an additional 873,133 shares in the last quarter. Redmile Group LLC increased its stake in shares of Atara Biotherapeutics by 1.7% during the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after buying an additional 156,863 shares during the period. BNP Paribas Financial Markets raised its holdings in Atara Biotherapeutics by 29.3% in the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 86,842 shares in the last quarter. Finally, Delap Wealth Advisory LLC purchased a new position in Atara Biotherapeutics in the first quarter worth approximately $29,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Performance

ATRA stock opened at $12.00 on Monday. The firm has a market cap of $69.12 million, a PE ratio of -0.47 and a beta of 0.50. Atara Biotherapeutics has a one year low of $6.50 and a one year high of $39.50. The firm’s 50 day moving average price is $9.00 and its 200-day moving average price is $10.18.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period last year, the company earned ($16.50) EPS. Equities research analysts predict that Atara Biotherapeutics will post -12.12 EPS for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.